Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04161482 · ClinicalTrials.gov registry record · Phase 1
An Open Label Study to Evaluate the Impact of Duration of Subcutaneous Infusion of a Novel, pH Neutral Formulation of Furosemide (Furoscix®) on Safety and Local Skin Tolerability
A Phase 1 study, sponsored by scPharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT04161482: Completed Phase 1 study, sponsored by scPharmaceuticals.
NCT04161482 is a Phase 1 study that has completed, run by scPharmaceuticals. The registered enrollment target is 39 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04161482, a Phase 1 study, has completed, sponsored by scPharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
This is a Phase 1 study to evaluate the safety and tolerability of shortened subcutaneous infusions of Furoscix.
Interventions
- DRUG Furosemide 80 mg (8 mg/mL)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2019-12-02 |
| Est. Completion | 2020-06-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04161482
The ClinicalTrials.gov registry entry for NCT04161482 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is scPharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Furosemide 80 mg (8 mg/mL) is the first listed.
NCT04161482 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04161482 about?
NCT04161482 is a clinical study titled "An Open Label Study to Evaluate the Impact of Duration of Subcutaneous Infusion of a Novel, pH Neutral Formulation of Furosemide (Furoscix®) on Safety and Local Skin Tolerability". This is a Phase 1 study to evaluate the safety and tolerability of shortened subcutaneous infusions of Furoscix.
What is the current status of trial NCT04161482?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2019-12-02. Estimated completion is 2020-06-26.
What interventions are being tested in trial NCT04161482?
The interventions under investigation include: Furosemide 80 mg (8 mg/mL) (DRUG).
Who is sponsoring clinical trial NCT04161482?
This trial is sponsored by scPharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.